Literature DB >> 10894278

The values of quantitative serum HIV-1 RNA levels and CD4 cell counts for predicting survival time among HIV-positive individuals with CD4 counts of < or = 50 x 10(6) cells/l.

E P Coakley1, M H Samore, J M Gillis, M D Hughes, S M Hammer.   

Abstract

OBJECTIVE: To evaluate the HIV-1 RNA level as a predictor of survival time among individuals with advanced AIDS.
METHODS: The serum HIV-1 RNA level, the CD4 cell count, and other clinical variables were evaluated at baseline, as predictors of survival time, among 56 retrospectively identified HIV-1 positive individuals with < or = 50 x 10(6) CD4 cells/l who attended the Beth Israel Deaconess Medical Center, Division of Infectious Diseases, between 1 July 1989 and 30 September 1993.
RESULTS: During follow-up, 55 of these 56 patients died. The median survival time was 20.5 months. In univariate Cox proportional hazard modeling neither the baseline HIV-1 RNA level nor the CD4 cell count were predictive of survival time. However, in multivariate models longer survival time was associated with the use of trimethoprim-sulphamethoxazole at entry [hazard ratio (HR), 0.42; P = 0.007], whereas shorter survival time was associated with a history of an AIDS-defining illness other than Pneumocystis carinii pneumonia (HR, 2.87; P = 0.007). Correlative analysis revealed a modest correlation of the baseline CD4 cell count with survival time (Spearman p = 0.41; P = 0.002). However, no correlation was found between HIV RNA levels and survival time (P = 0.5).
CONCLUSIONS: In this population with very advanced disease, the HIV-1 RNA level was a poor discriminator of survival time, being inferior to the CD4 cell count and to specific clinical variables such as the nature of the prior AIDS-defining illness and the type of Pneumocystis carinii pneumonia prophylaxis employed. Among individuals with advanced AIDS, these data emphasize the relative importance of the CD4 cell count and of specific clinical factors, over the HIV-1 RNA level in predicting survival time.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10894278     DOI: 10.1097/00002030-200006160-00011

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  5 in total

Review 1.  Immune-based therapies: an adjunct to antiretroviral treatment.

Authors:  Jeffrey M Jacobson
Journal:  Curr HIV/AIDS Rep       Date:  2005-06       Impact factor: 5.071

2.  Change over time of mortality predictors after HAART initiation in a Senegalese cohort.

Authors:  Pierre De Beaudrap; Jean-François Etard; René Ecochard; Assane Diouf; Allé Baba Dieng; Vannina Cilote; Ibrahima Ndiaye; Ndèye Fatou Ngom Guèye; Pape Mandoumbé Guèye; Papa Salif Sow; Souleymane Mboup; Ibra Ndoye; Eric Delaporte
Journal:  Eur J Epidemiol       Date:  2008-01-16       Impact factor: 8.082

3.  A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy.

Authors:  Jeffrey M Jacobson; Hongying Wang; Rebeka Bordi; Lu Zheng; Barry H Gross; Alan L Landay; John Spritzler; Jean-Pierre Routy; Constance Benson; Judith Aberg; Pablo Tebas; David W Haas; Jennifer Tiu; Kristine Coughlin; Lynette Purdue; Rafick-Pierre Sekaly
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-01       Impact factor: 3.731

4.  Clinical therapeutic effects of topical agents in adult patients with human immunodeficiency virus-related oral mucosa ulcers: A protocol for systematic review and meta-analysis.

Authors:  Xiuming Ding; Feihu Xu; Xiang Zhang
Journal:  Medicine (Baltimore)       Date:  2021-02-12       Impact factor: 1.817

5.  The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda.

Authors:  Brian K Kigozi; Samwel Sumba; Peter Mudyope; Betty Namuddu; Joan Kalyango; Charles Karamagi; Mathew Odere; Elly Katabira; Peter Mugyenyi; Francis Ssali
Journal:  AIDS Res Ther       Date:  2009-07-24       Impact factor: 2.250

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.